Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018100534) COMBINATION THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/100534 International Application No.: PCT/IB2017/057548
Publication Date: 07.06.2018 International Filing Date: 30.11.2017
IPC:
A61K 39/00 (2006.01) ,A61K 31/415 (2006.01) ,A61K 31/4155 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB/GB]; 980 Great West Road Brentford, Middlesex TW8 9GS, GB
Inventors:
BARBASH, Olena; US
FEDORIW, Andy; US
KORENCHUK, Susan; US
MOHAMMAD, Helai; US
SHERK, Christian; US
Priority Data:
62/428,75701.12.2016US
62/433,35913.12.2016US
Title (EN) COMBINATION THERAPY
(FR) POLYTHÉRAPIE
Abstract:
(EN) In one embodiment, the present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, methods for treating cancer in a human in need thereof are provided, the methods comprising administering to the human the combinations or pharmaceutical compositions provided herein.
(FR) Dans un mode de réalisation, la présente invention concerne une combinaison d'un inhibiteur de la protéine arginine méthyltransférase de Type I (PRMT Type I) et d'un agent immunomodulateur sélectionné parmi: un anticorps anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci, un anticorps anti-PDL1 ou un fragment de liaison à l'antigène de celui-ci, et un anticorps anti-OX40 ou un fragment de liaison à l'antigène de celui-ci. Dans un autre mode de réalisation, la présente invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un inhibiteur de la protéine arginine méthyltransférase de Type I (PRMT Type I) et une seconde composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un agent immunomodulateur choisi parmi : un anticorps anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci, un anticorps anti-PDL1 ou un fragment de liaison à l'antigène de celui-ci, et un anticorps anti-OX40 ou un fragment de liaison à l'antigène de celui-ci. Dans un autre mode de réalisation, l'invention concerne des procédés de traitement du cancer chez un être humain en ayant besoin, les procédés comprenant l'administration à l'humain des combinaisons ou des compositions pharmaceutiques fournies ici.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)